{"nctId":"NCT01748448","briefTitle":"Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome","startDateStruct":{"date":"2012-12","type":"ACTUAL"},"conditions":["Cutaneous Malignant Melanoma"],"count":436,"armGroups":[{"label":"Vitamin D","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vitamin D"]},{"label":"Placebo: Oil","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo: Oil"]}],"interventions":[{"name":"Vitamin D","otherNames":["D-Cure","Cholecalciferol"]},{"name":"Placebo: Oil","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Older than 18 years and younger than 80 years of age.\n2. Histologically proven malignant melanoma, stage one B (IB) to three (III) Not participating in other clinical trial.\n3. The only treatment for melanoma is surgical treatment.\n4. Complete resection of melanoma.\n5. Single primary invasive cutaneous melanoma\n6. Signed ethical committee approved informed consent\n7. Serum phosphate, serum calcium at the entry of the study within normal limits of laboratory reference\n\nExclusion criteria\n\n1. Pregnant/lactating women or planning on becoming pregnant during the study\n2. Known hypersensitivity to vitamin D or its components.\n3. Pre-existing renal stone disease, chronic renal disease with glomerular filtration rate (eGFR) \\< 30 mL/min/1.73 m2 or renal dialysis.\n4. Liver failure or chronic liver disease with liver enzymes \\> 2 fold upper limit of normal (ULN).\n5. History of parathyroid disease or granulomatous disease (TBC and sarcoidosis)\n6. History of malabsorption syndrome or any medical condition that might interfere with vitamin D absorption.\n7. History of small intestine resection.\n8. History of other malignancy within the last 5 years except for carcinoma in situ of the cervix or basal cell carcinoma or squamous cell carcinoma of the skin or in situ malignant melanoma.\n9. Chronic alcohol abuse.\n10. Medical or logistic problems likely to preclude completion of the study.\n11. Taking medication that predisposes to hypercalcemia (digoxin, lithium, thiazide diuretics) or taking medication that would affect metabolism of vitamin D (anticonvulsants, corticosteroids, H2-receptor antagonists)\n12. Intake of vitamin D supplements within 6 months prior to entry of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Relapse Free Survival","description":"Disease free survival will be the primary endpoint of this phase III trial. Study duration for one patient is maximum 9 years and 7 months. Patients are supplemented with studymedication (Vitamin D or placebo) for maximum 3.5 years. This is the treatment period. After the treatment period (in which the patients take study medication, placebo or Vitamin D), there is the follow-up period, no more study medication is taken, the study is still double blind, and the patients are followed at the clinical department for relapse and/or death.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Melanoma Subtype, as Assessed Clinically and Histologically","description":"Vitamin D levels at diagnosis will be correlated with melanoma subtype, as assessed clinically and histologically.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Melanoma Site, as Clinically Recorded","description":"Vitamin D levels at diagnosis will be correlated with melanoma site, as clinically recorded.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"27","spread":null}]},{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"61","spread":null}]},{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"25(OH)D3 Serum Levels","description":"25(OH)D3 serum levels will be recorded at diagnosis and at 6 months intervals up to final study visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":"9"},{"groupId":"OG001","value":"23","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":"11"},{"groupId":"OG001","value":"23","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":"11"},{"groupId":"OG001","value":"24","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":"11"},{"groupId":"OG001","value":"24","spread":"11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":"11"},{"groupId":"OG001","value":"24","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":"12"},{"groupId":"OG001","value":"27","spread":"8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":"12"},{"groupId":"OG001","value":"25","spread":"7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":"12"},{"groupId":"OG001","value":"27","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Stage of Melanoma Patient","description":"Stage of melanoma patient at diagnosis according to the 8th American Joint Committee of Cancer (AJCC) Melanoma staging and classification.\n\nThe eighth edition of the AJCC staging system is currently the most widely accepted and standardized approach to melanoma staging and classification at initial diagnosis. Melanoma staging is based on the American Joint Committee on Cancer (AJCC) staging system that uses three key pieces of information for assigning Tumor-Node-Metastasis (TNM) classifications. AJCC staging ifacilitates accurate risk stratification and is essential to guide patient treatment.\n\nThe higher the stage, the more severe the melanoma.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"108","spread":null}]},{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"30","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Safety Endpoints:Incidence and Severity of Adverse Events","description":"Incidence and severity of adverse events will be recorded every 3 months up to final study visit (from the treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":218},"commonTop":["Endocrine disorders","Infections and infestations","Musculoskeletal and connective tissue disorders","Respiratory, thoracic and mediastinal disorders","Gastrointestinal disorders"]}}}